Tradjenta, which was approved by the FDA in May 2011 (#msg-62668535) and by the CHMP is Jun 2011 (#msg-64617999), is the drug from B-I that caused LLY to pull out of its partnership with AMLN following a period brief litigation (#msg-68775229, #msg-63176632).